Medically Reviewed by: Dr. Dipak Ladda, M.D.
Expertise: Consultant Pathologist
Last Updated: July 27, 2026
Medical Analysis
Advanced Comprehensive Clinical Guide to Factor V Leiden Mutation Diagnosis, Pathology, and Molecular Testing
Introduction to Factor V Leiden Pathophysiology and Genetic Inheritance Mechanisms
Factor V is an essential protein involved in blood clotting, and the Factor V Leiden gene change, also called mutation, is linked to an increase risk of blood clots; most commonly in legs and lungs [3, 5]. Most people with factor V Leiden never develop abnormal clots [5, 11]. The mutated gene with change in F5 gene is inherited in an autosomal recessive manner [4, 10]. So that to develop the disease; this gene is supposed to come from both parents [4, 10]. Inheritance: Semi-dominant [5]. Penetrance: Heterozygotes carry risk of 10 percent while homozygotes 80 percent of occurrence of thrombotic phenomenon [5, 11].
Clinical Indications and Diagnostic Criteria for Factor V Leiden Mutation Testing
Venous Thromboembolism; especially if it occurs before 50 yrs of age [5, 11]
Assessment of case [7]
If there is family history of Venous Thromboembolism [5, 11]
To monitor treatment in case of Venous Thromboembolism [7]
Atypical sites of clotting like visceral vein thrombosis like an ovarian vein, portal vein, or renal vein thrombosis [7, 11]
Molecular Laboratory Methods of Estimation and Genetic Assay Techniques
Polymerase Chain Reaction (PCR), Restriction Fragment Length Polymorphism (RFLP), Real-Time PCR (qPCR), DNA Sequencing (Sanger or Next-Generation), Amplification-Refractory Mutation System (ARMS), Denaturing Gradient Gel Electrophoresis (DGGE), DNA Microarray Hybridization, Enzyme-Linked Immunosorbent Assay (ELISA) [5, 7].
Pre-Analytical Protocols, Patient Counseling, and Informed Consent Requirements
Proper counseling to patient and his/her relatives is must [7]. Informed consent must be obtained; as it is a genetic test [7].
Comprehensive Sample Collection, Whole Blood Processing, and Buccal Swab Protocols
5.0 ml whole blood (Lavender-top (EDTA) tube, yellow-top (ACD) tube) [7]. Buccal swabs obtained in the kits provided (Better to take two swabs for one testing) [7]. BLOOD SAMPLE: Collect 5.0 blood in EDTA (Lavender capered) tube or Citrate (Green capped) tube [7]. Heparin should be avoided since it may interfere with downstream polymerase chain reaction (PCR) applications [7]. Separate the plasma immediately and freeze it [7]. Send minimum of 0.5ml sample of plasma [7]. Don’t thaw it before it reach to lab [7]. Press firmly and twirl the cheek brush against the inside of the inner cheek using an up and down motion from front to back and back to front [7]. Use a stopwatch to time the collection for at least 30 seconds per swab to collect cells [7]. It is important to collect samples from maximum mucosal surfaces [7]. Place dried swabs and packaging into an appropriate paper transport container, preferably an evidence collection envelope [7]. Seal with evidence tape and transport to the laboratory [7]. Polystyrene transporting containers should be maintained at 4°C (with ice or cold pack) during transportation of the samples [7]. Alternatively, if processing is to occur at a later time, the buccal swab/cytobrush sample can be transferred to a cryovial, which can then be stored at -80°C [7].
Pre-Analytical Plasma Processing and Specimen Storage Stability Guidelines
How to collect, process and store plasma for ctDNA analysis? (A) Blood draw (B) Centrifuge (C) Storage [7]. Blood draw with an anticoagulant such as EDTA [7]. Centrifuge at 1200-1600 g, 10 minutes [7]. Harvest supernatant [7]. Second high-speed centrifuge at 3000-16,000 g, 10 minutes [7]. Take supernatant into fresh tube [7]. Store at -80°C [7]. Specimen Storage: Ambient 72 hours, Refrigerated 1 week, Frozen 1 month [7].
Interpretation of Results for Factor V Leiden Mutation and Laboratory Reporting Standards
Results For Factor V Leiden Mutation Test Result [7]. Result: Negative [7]. Last Result 3003 [7]. Negative: The sample submitted is negative for factor V Leiden, R506Q mutation [5, 7].
Diagnostic Utility and Clinical Decision Support Frameworks
| Diagnostic Utility | Description |
| Risk assessment | Identifies genetic thrombophilia risk [5, 11] |
| Explanation of unexplained VTE | Clarifies unprovoked, early-onset thrombotic events [5, 11] |
| Recurrent thromboembolism evaluation | Assesses cause in repeated venous clots [5, 11] |
| Family screening | Detects asymptomatic carriers in thrombophilic families [5, 10] |
| Pregnancy-related thrombosis risk | Evaluates risk in recurrent pregnancy loss or complications [5, 11] |
| Anticoagulation guidance | Informs need/duration of blood thinning therapy [5, 7] |
Clinical Significance, Thrombotic Risk Stratification, and Associated Complications
| Clinical Significance | Details |
| Increased risk of venous thromboembolism (VTE) | Heterozygous carriers have 5-7 fold higher risk; homozygous up to 25-50 fold higher [5, 11] |
| Common in Caucasians | Prevalence 1-5% general population; higher in VTE patients [5, 11] |
| Incomplete penetrance | Many carriers never develop thrombosis [5, 11] |
| Risk factors interaction | Combined with other thrombophilias or acquired risk factors increases VTE risk [5, 11] |
| Limited role in arterial thrombosis | No clear association with heart attacks or strokes [5, 11] |
| Pregnancy & postpartum | Increases risk of VTE complications during pregnancy and postpartum [5, 11] |
| Family history relevance | Increased risk if relatives had VTE before 50 years [5, 11] |
| Testing utility | Identifies cause of unprovoked or recurrent thrombosis [5, 11] |
Diagnostic Limitations, Assay Constraints, and Potential Sources of Error
Diagnostic errors can occur due to rare sequence variations [5, 7]. F5 gene mutations, other than p.Arg534Gln, will not be detected [5, 7].
For Non-Medicos
What Is Factor V Leiden? A Simple Guide to Blood Clots and Genetics
Understanding Factor V and Blood Clotting Basics
Factor V is a vital protein that helps your blood clot normally [3, 6]. When a change or mutation occurs in this gene, known as Factor V Leiden, it increases your tendency to form abnormal blood clots, most frequently in the deep veins of your legs or your lungs [3, 5]. However, having this genetic change does not mean you will definitely develop dangerous clots; in fact, most carriers never experience any issues [5, 11]. This gene alteration is inherited from your parents, and its effects depend on whether you received the altered gene from one or both parents [4, 5, 10].
When Do Doctors Order This Test?
Physicians typically recommend testing if you have experienced a venous blood clot before the age of 50, if you have a family history of unusual blood clotting disorders, or if you develop clots in rare, unusual locations like the liver or kidneys [5, 7, 11].
Sample Collection and Laboratory Testing Explained
To test for Factor V Leiden, medical professionals collect a small blood sample using specialized tubes or perform a quick, painless cheek swab [7]. Special care is taken during handling, keeping samples cold or frozen, to ensure the laboratory can accurately analyze your DNA using advanced methods like PCR and gene sequencing [5, 7].
What Your Test Results Mean for Your Health
A negative result means the specific Factor V Leiden mutation was not found in your sample [5, 7]. Understanding your status helps doctors assess your personal risk for venous thromboembolism, guide safe pregnancy management, and determine if other family members should be screened [5, 10, 11].
References:
Mann, K. G. (1999). Biochemistry and physiology of blood coagulation. Thrombosis and Haemostasis, 82(2), 165–174.
Furie, B., & Furie, B. C. (2005). Thrombus formation in vivo. Journal of Clinical Investigation, 115(12), 3355–3362.
Dahlbäck, B. (2003). Blood coagulation. The Lancet, 361(9369), 1627–1632.
Mannucci, P. M., & Duga, S. (2008). Phenotypes and genotypes of rare bleeding disorders. Haemophilia, 14(3), 41–49.
Bertina, R. M., Koeleman, B. P., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994). Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369(6475), 64–67.
Esmon, C. T. (2000). Regulation of blood coagulation. Biochimica et Biophysica Acta (BBA) – Protein Structure and Molecular Enzymology, 1477(1-2), 349–360.
Triplett, D. A. (2000). Coagulation assays. American Journal of Clinical Pathology, 114(Suppl 1), S98–S111.
Hoffman, M., & Monroe, D. M. (2001). A cell-based model of hemostasis. Thrombosis and Haemostasis, 85(6), 958–965.
Mammen, E. F. (1998). Coagulation abnormalities in liver disease. The Gastroenterologist, 6(1), 16–23.
Seligsohn, U., & Zivelin, A. (2007). The genetics of hereditary blood clotting disorders. Thrombosis and Haemostasis, 98(1), 101–109.
Lane, D. A., Grant, P. J., & Gray, S. (1994). Genetic risk factors for venous thrombosis. Blood Coagulation & Fibrinolysis, 5(5), 785–799.
FAQ’s:
What is Factor V Leiden?
A genetic mutation linked to an increased risk of abnormal blood clots in legs and lungs.How is the gene inherited?
Inherited in an autosomal recessive manner, meaning the altered gene is supposed to come from both parents.What are the testing indications?
Indications include venous thromboembolism before age 50, family history, and atypical clotting sites.What methods estimate the mutation?
Techniques include Polymerase Chain Reaction, DNA sequencing, RFLP, qPCR, and Enzyme-Linked Immunosorbent Assay.What is required before collection?
Proper patient and relative counseling must be completed, and informed consent must be obtained.How should blood samples be processed?
Collect whole blood in EDTA or citrate tubes, separate plasma immediately, and freeze it.What is the buccal swab protocol?
Twirl cheek brush against inner cheek surfaces for at least 30 seconds per swab.What are the specimen storage limits?
Ambient for 72 hours, refrigerated for 1 week, and frozen for 1 month.What does a negative result mean?
The submitted sample is negative for the factor V Leiden, R506Q mutation.
What is the clinical significance?
Heterozygous carriers have a 5-7 fold higher risk of venous thromboembolism, while homozygotes face up to 50 times higher risk.
